

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016

Particulars	Quarter Ended			Rs. In Lakhs
	30-Jun-2016	31-Mar-2016	30-Jun-2015	Previous Period Ended
	(Unaudited)	(Audited)	(Audited)	9 months (Audited)
<b>1 Income from operations</b>				
(a) Net Sales/Income from operations (Net of excise duty)	1,309.83	1,745.91	2,503.78	5,447.02
(b) Other Operating Income	78.36	109.06	72.19	279.94
<b>Total income from operations (net)</b>	<b>1,388.19</b>	<b>1,854.97</b>	<b>2,575.97</b>	<b>5,726.96</b>
<b>2 Expenses</b>				
(a) Cost of Materials Consumed	696.55	736.31	948.27	2,345.49
(b) Purchase of traded goods	110.13	390.31	289.41	908.25
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(157.64)	57.73	411.74	167.57
(d) Employee benefits expense	237.16	226.32	202.37	658.11
(e) Depreciation and amortisation expense	89.33	87.30	90.39	264.02
(f) Other expenses	267.69	274.89	306.36	853.79
<b>Total expenses</b>	<b>1,243.22</b>	<b>1,772.86</b>	<b>2,248.54</b>	<b>5,197.23</b>
<b>3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional Items (1-2)</b>	<b>144.97</b>	<b>82.11</b>	<b>327.43</b>	<b>529.73</b>
<b>4 Other Income</b>	<b>14.54</b>	<b>293.67</b>	<b>20.50</b>	<b>1,124.11</b>
<b>5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>159.51</b>	<b>375.78</b>	<b>347.93</b>	<b>1,653.84</b>
<b>6 Finance costs</b>	<b>378.22</b>	<b>377.28</b>	<b>446.80</b>	<b>1,144.35</b>
<b>7 Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5-6)</b>	<b>(218.71)</b>	<b>(1.50)</b>	<b>(98.87)</b>	<b>509.49</b>
<b>8 Exceptional Items (Net)</b>	<b>(2.16)</b>	<b>(84.92)</b>	<b>124.07</b>	<b>(60.23)</b>
<b>9 Prior Period Adjustments</b>	<b>-</b>	<b>(35.78)</b>	<b>-</b>	<b>87.70</b>
<b>10 Profit/(Loss) from Ordinary Activities before tax (7-8-9)</b>	<b>(216.55)</b>	<b>119.20</b>	<b>25.20</b>	<b>482.02</b>
<b>11 Tax Expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>12 Net Profit/(Loss) from Ordinary activities after tax (10-11)</b>	<b>(216.55)</b>	<b>119.20</b>	<b>25.20</b>	<b>482.02</b>
<b>13 Extraordinary Item (net of tax expenses)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>14 Net Profit/(Loss) for the period (12+13)</b>	<b>(216.55)</b>	<b>119.20</b>	<b>25.20</b>	<b>482.02</b>
<b>15 Paid up equity share capital (face value Rs.10/- per share)</b>	<b>2,204.00</b>	<b>2,204.00</b>	<b>2,158.00</b>	<b>2,204.00</b>
<b>16 Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,076.01</b>
<b>17 I Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))</b>				
(a) Basic	(0.99)	0.53	0.10	2.17
(b) Diluted	(0.99)	0.53	0.10	2.17
<b>17 II Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))</b>				
(a) Basic	(0.99)	0.53	0.10	2.17
(b) Diluted	(0.99)	0.53	0.10	2.17



Cont'd... 2

Notes:

- 1) The above financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12<sup>th</sup> August, 2016.
- 2) During the quarter the Company has charged Rs. 21.18 lacs to Statement of Profit & Loss, being depreciation on revalued assets.
- 3) During the Quarter the Company has capitalised interest of Rs 20.44 lacs and allocable expenses of Rs 6.27 lacs towards Ankleshwar Unit Expansion/ Upgradation.
- 4) The Company has one Single Segment "Pharmaceuticals".
- 5) Figures for pervious period have been regrouped/ rearranged wherever necessary, to conform to the relevant current period classification.

For LYKA LABS LIMITED

N.L. GANDHI (DIN:00021530)  
Chairman & Managing Director

Mumbai  
12-Aug-2016

LYKA LABS LIMITED				
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016				
(Rs. in Lakhs)				
Particulars	Quarter Ended			Previous Period Ended
	30-06-2016 (Unaudited)	31-03-2016 (Audited)	30-06-2015 (Unaudited)	31-03-2016 9 Months (Audited)
<b>1</b>	<b>Income from operations</b>			
	(a) Net Sales/Income from operations (Net of excise duty)	2005.52	3273.42	4638.70
	(b) Other Operating Income	112.45	181.76	139.78
	<b>Total income from operations (net)</b>	<b>2117.97</b>	<b>3455.18</b>	<b>4778.48</b>
<b>2</b>	<b>Expenses</b>			
	(a) Cost of Materials Consumed	696.55	943.70	948.27
	(b) Purchase of traded goods	327.82	912.84	1161.03
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(123.63)	90.21	397.98
	(d) Employee benefits expense	443.54	402.70	435.18
	(e) Depreciation and amortisation expense	252.51	249.78	260.08
	(f) Other expenses	532.46	709.80	773.02
	<b>Total expenses</b>	<b>2129.25</b>	<b>3309.03</b>	<b>3975.56</b>
<b>3</b>	<b>Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional Items (1-2)</b>	<b>(11.28)</b>	<b>146.15</b>	<b>802.92</b>
<b>4</b>	<b>Other Income</b>	<b>21.67</b>	<b>16.94</b>	<b>28.03</b>
<b>5</b>	<b>Profit/(Loss) from ordinary activities before finance cost and exceptional Items (3+4)</b>	<b>10.39</b>	<b>163.09</b>	<b>830.95</b>
<b>6</b>	<b>Finance costs</b>	<b>426.14</b>	<b>450.89</b>	<b>534.12</b>
<b>7</b>	<b>Profit/(Loss) from ordinary activities after finance costs but before exceptional Items (5-6)</b>	<b>(415.75)</b>	<b>(287.80)</b>	<b>296.83</b>
<b>8</b>	<b>Exceptional Items (Net)</b>	<b>0.01</b>	<b>(1,138.57)</b>	<b>(20.94)</b>
<b>9</b>	<b>Prior Period Items</b>	<b>-</b>	<b>-</b>	<b>(123.47)</b>
<b>10</b>	<b>Profit/(Loss) from Ordinary Activities before tax (7+8+9)</b>	<b>(415.76)</b>	<b>(1,426.37)</b>	<b>275.89</b>
<b>11</b>	<b>Tax Expenses</b>	<b>0.16</b>	<b>251.53</b>	<b>-</b>
<b>12</b>	<b>Net Profit/(Loss) from Ordinary activities after tax (10-11)</b>	<b>(415.92)</b>	<b>(1,677.90)</b>	<b>275.89</b>
<b>13</b>	<b>Extraordinary Item (net of tax expenses)</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>14</b>	<b>Net Profit/(Loss) for the period</b>	<b>(415.92)</b>	<b>(1,677.90)</b>	<b>275.89</b>
<b>15</b>	<b>Share of Profit/(Loss) of associates</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>16</b>	<b>Minority interest</b>	<b>(2.25)</b>	<b>(478.43)</b>	<b>(107.39)</b>
<b>17</b>	<b>Net Profit/(Loss) after taxes, minority interest and share of profit / (loss) of associates</b>	<b>(413.66)</b>	<b>(1,199.47)</b>	<b>168.50</b>

LYKA LABS LIMITED					
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016					
(Rs.in Lakhs)					
Particulars	Quarter Ended			Previous Period Ended	
	30-06-2016 (Unaudited)	31-03-2016 (Audited)	30-06-2015 (Unaudited)	31-03-2016 9 Months (Audited)	
18	Paid up equity share capital (face value Rs.10/- per share)	2204.00	2204.00	2158.00	2,204.00
19	Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year				1,527.19
20	i Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)				
	(a) Basic	(1.89)	(5.45)	0.77	1.65
	(b) Diluted	(1.89)	(5.45)	0.77	1.65
21	ii Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised)				
	(a) Basic	(1.89)	(5.45)	0.77	1.65
	(b) Diluted	(1.89)	(5.45)	0.77	1.65




Cont'd... 3

Notes:

- 1) The above financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12<sup>th</sup> August, 2016.
- 2) During the quarter the Holding Company has charged Rs. 21.18 lacs to Statement of Profit & Loss, being depreciation on revalued assets.
- 3) During the Quarter the Holding Company has capitalised interest of Rs 20.44 lacs and allocable expenses of Rs 6.27 lacs towards Ankleshwar Unit Expansion/ Upgradation.
- 4) The Company has one Single Segment "Pharmaceuticals".
- 5) Figures for pervious period have been regrouped/ rearranged wherever necessary, to conform to the relevant current period classification.

For LYKA LABS LIMITED

  
N.L. GANDHI (DIN: 00021530)  
Chairman & Managing Director

Mumbai  
12-Aug-2016

